Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490996 | ||
| 003 | CHVBK | ||
| 005 | 20210128100507.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0746-7 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0746-7 | ||
| 245 | 0 | 0 | |a Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer |h [Elektronische Daten] |c [Keisuke Shigeta, Takeo Kosaka, Satoshi Yazawa, Yota Yasumizu, Ryuichi Mizuno, Hirohiko Nagata, Kazunobu Shinoda, Shinya Morita, Akira Miyajima, Eiji Kikuchi, Ken Nakagawa, Shintaro Hasegawa, Mototsugu Oya] |
| 520 | 3 | |a Background: The aim of this study is to identify factors that increase the occurrence of severe neutropenia (SN) and febrile neutropenia (FN) during docetaxel treatment for castration-resistant prostate cancer (CRPC). Methods: We retrospectively reviewed 258 courses during the first three cycles among 95 patients. Docetaxel at a dose of 75mg/m2 was administered every 3 or 4weeks. Patient background, laboratory data, and bone scan results were collected to assess predictive factors for SN and FN. We defined SN as an absolute neutrophil count (ANC)of <500/mm3 and defined FN as an ANCof <1000/mm3 with a body temperature of >38.3°C. Results: The mean age of the patients was 72.6±6.4 years and the mean prostate-specific antigen was 135.4±290.9ng/ml. During the first three courses of treatment, SN occurred in 72.6% of patients and FN occurred in 9.5% of patients. Univariate analysis demonstrated that age≥75 years (p=0.002), number of comorbidities≥1.2 (p=0.008 and p=0.006) and previous external beam radiation therapy (EBRT) (p=0.001) were predictive factors for the development of SN or FN. In multivariate analysis, significant predictors of SN or FN were age≥75 years (hazard ratio [HR] 5.77; p=0.004) and previous EBRT (HR 14.5; p=0.012). According to the subgroup analysis dividing SN and FN separately, multivariate analysis also revealed that age≥75 years and previous EBRT were also significant predictors for developing SN (HR 5.09; p=0.023, HR 12.7; p=0.020, respectively) and for developing FN (HR 5.45; p=0.042, HR 7.72; p=0.015, respectively). Conclusions: Patients aged≥75years and with a history of localized radiation therapy are at higher risk for significant neutropenic events and require closer surveillance. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Severe neutropenia |2 nationallicence | |
| 690 | 7 | |a Febrile neutropenia |2 nationallicence | |
| 690 | 7 | |a Docetaxel |2 nationallicence | |
| 690 | 7 | |a Predictive factor |2 nationallicence | |
| 690 | 7 | |a Castration-resistant prostate cancer |2 nationallicence | |
| 700 | 1 | |a Shigeta |D Keisuke |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kosaka |D Takeo |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yazawa |D Satoshi |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yasumizu |D Yota |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Mizuno |D Ryuichi |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Nagata |D Hirohiko |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Shinoda |D Kazunobu |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Morita |D Shinya |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Miyajima |D Akira |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kikuchi |D Eiji |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Nakagawa |D Ken |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Hasegawa |D Shintaro |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Oya |D Mototsugu |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 605-612 |x 1341-9625 |q 20:3<605 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0746-7 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0746-7 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shigeta |D Keisuke |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kosaka |D Takeo |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yazawa |D Satoshi |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yasumizu |D Yota |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mizuno |D Ryuichi |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nagata |D Hirohiko |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shinoda |D Kazunobu |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Morita |D Shinya |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Miyajima |D Akira |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kikuchi |D Eiji |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nakagawa |D Ken |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hasegawa |D Shintaro |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Oya |D Mototsugu |u Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 605-612 |x 1341-9625 |q 20:3<605 |1 2015 |2 20 |o 10147 | ||